SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's stock is trending amid upgrades from analysts, though some community members express concern over valuation relative to competitors and potential interconnect hurdles in the AI sector. Despite strong earnings, the stock experienced a selloff, leading to discussions about a possible short squeeze and whether AI constitutes a bubble.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing heavy volatility, sparking discussions about a potential market correction and whether dip-buying strategies will continue to pay off. Some community members are pointing to broader macroeconomic concerns and the influence of crypto markets, while others are eyeing key support levels for potential reversals. The conversation highlights uncertainty around near-term market direction.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to strong Q3 earnings and raised FY26 guidance, sparking bullish sentiment among investors; discussions include the impact of e-commerce growth and a planned move to the Nasdaq. Community members are debating whether Walmart's performance signals broader economic strength or if it's a safe haven during market uncertainty, while also pondering its valuation relative to tech companies.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, frustrating investors who cite strong deliveries and question the stock's valuation relative to peers. Community members speculate about market manipulation and potential short squeezes while bracing for upcoming earnings. Despite the negative price action, some investors remain optimistic, viewing the current dip as a buying opportunity based on the company's long-term potential.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the price of Bitcoin fluctuates, impacting MicroStrategy's value as a major BTC holder; the community is closely watching key support levels. Discussions revolve around analyst Tom Lee's commentary and potential short squeezes, with some expressing concerns about solvency and potential liquidation. Recent whale activity and overall market sentiment add to the volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess its volatile movements amidst optimism in the AI sector. Community discussions revolve around dip-buying strategies and potential profit-taking points, especially with upcoming earnings from key semiconductor players like NVDA. The ongoing government shutdown and concerns about AI valuations add to the uncertainty surrounding this leveraged ETF.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst overall crypto market volatility and the launch of new ETFs, sparking debates on their potential impact. Community discussions revolve around whether XRP can decouple from Bitcoin's influence and the significance of upcoming ISO20022 compliance. Some traders express frustration with price stagnation, while others remain optimistic about long-term utility and institutional adoption.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Los Angeles Capital Management LLC Purchases Shares of 43,422 Replimune Group, Inc. $REPL

Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The...

FY2026 EPS Forecast for Replimune Group Decreased by Analyst

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2026 earnings per share (EPS) estimates for Replimune Group in a report issued on...

171,527 Shares in Replimune Group, Inc. $REPL Purchased by Candriam S.C.A.

Candriam S.C.A. acquired a new position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities...

Nan Fung Trinity HK Ltd. Makes New Investment in Replimune Group, Inc. $REPL

Nan Fung Trinity HK Ltd. purchased a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the...

<ul class="summary-bullets"><li>FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.</li><li>Prescription Drug User Fee Act decision date is set for April 10, 2026.</li><li>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4.</li></ul>Replimune Group Inc.(REPL) on Monday announced that it has cleared a major regulatory hurdle after the U.S. Food and Drug Administration (FDA) accepted its resubmitted Biologics License Application (BLA) for RP1, a treatment for advanced melanoma.The FDA has set April 10, 2026, as the Prescription Drug User Fee Act (PDUFA) target action date for this Class II resubmission.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/REPL">Replimune stock</a>&nbsp;traded over 98% higher on Monday morning and was the third most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day while message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">What Is RP1?</h2>RP1 is Replimune’s lead therapy candidate. It is derived from a modified herpes simplex virus, engineered to enhance tumor cell destruction and stimulate the body’s immune system against cancer. The therapy is designed with a fusogenic protein (GALV-GP R-) and GM-CSF to amplify both tumor-killing activity and the immune response.<blockquote>“RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma, who have progressed on PD-1 based therapy."- Sushil Patel, CEO, Replimune.</blockquote>The BLA resubmission follows several months of engagement between the company and the agency. Replimune worked to incorporate additional clinical data, detailed analyses and supporting documentation to address regulatory concerns.<h2 class="st-heading-2">What Are Analysts Saying?</h2>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4, according to TheFly. The firm sees the FDA’s quick response after a Type A meeting as an encouraging sign, suggesting the agency is open to the updated application with the new data included.Leerink analyst Jonathan Chang raised the firm’s rating to ‘Outperform’ from ‘Market Perform’ and lifted the price target to $13 from $3, expressing renewed confidence in RP1.&nbsp;Replimune stock has lost over 14% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sealsq-stock-jumps-13-today-company-s-first-chip-with-built-in-post-quantum-encryption-draws-attention/ch6CDEMR3Yn">SEALSQ Stock Jumps 13% Today: Company’s First Chip With Built-In Post-Quantum Encryption Draws Attention</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

What Is Driving Replimune Stock’s 98% Surge Today? 

FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.

Equity

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S. Food and Drug Administration. Shares of the company slumped 42% at the time of writing.The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.The company subsequently requested a meeting with the agency to push for approval of RP1. “We remain steadfastly committed to patient access while we work with the FDA to secure regulatory approval for RP1, however, without accelerated approval based on the current application, continuation of the RP1 program in advanced melanoma, including the phase 3 confirmatory trial, will not be viable,” CEO Sushil Patel said earlier this month.However, on Thursday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.replimune.com/news-releases/news-release-details/replimune-provides-update-following-type-meeting-fda">stated</a> that it had completed a meeting with the FDA on September 16 regarding the letter pertaining to the application for approval of RP1. The company stated that it is evaluating the feedback from the FDA to determine its next steps, and the path forward under the accelerated approval pathway has not yet been determined.“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” Patel reiterated on Thursday.RP1 is Replimune’s lead product candidate. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:571/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_11_25_42_AM_png_83a21ea942.webp" alt="REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="571" height="64"><figcaption>REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that a strategic review announcement is due in the coming months.<stembedurl>https://stocktwits.com/Bakhmutbull2/message/629140552</stembedurl>A more optimistic user, however, said that RP1 remains “a therapy to watch” for melanoma patients.<stembedurl>https://stocktwits.com/sousayuri/message/629114614</stembedurl>REPL stock is down by about 73% this year and by about 70% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-healthcare-reportedly-eyes-selling-stake-in-china-unit/chDcxTmR3bI">GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Replimune Stock Plunged 42% Today – Here’s Why

The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action. 

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of...

Retail&nbsp;trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral’, citing the sudden resignation of Vinay Prasad, former head of the FDA’s biologics division, as a key development that could improve the outlook for RP1, the company’s lead oncolytic immunotherapy candidate.The stock more than doubled Wednesday, closing up 101% at $7.55.Cantor analyst Li Watsek said the FDA’s Complete Response Letter (CRL) issued on July 22 for RP1 in combination with nivolumab was likely influenced by senior leadership, possibly Prasad, overruling the agency’s review team.&nbsp;Watsek sees Prasad’s exit as “removing a major obstacle” and believes the odds of RP1 receiving accelerated approval have “greatly improved.” Cantor expects Replimune shares could return to pre-CRL levels above $12 if the decision is overturned.BMO Capital analyst Evan Seigerman&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">also said</a> Prasad’s departure is a net positive for the biopharma sector, noting that a new FDA biologics director is “likely to be more permissive of innovation.” While BMO remains uncertain whether RP1 will be reconsidered, the firm expects shares to rally meaningfully on the change.<a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">Prasad stepped down</a> just two months into his role leading the FDA’s biologics division, after facing growing backlash over how he handled Sarepta’s Elevidys, the only approved gene therapy for Duchenne muscular dystrophy.Earlier this month, Prasad and FDA Commissioner Marty Makary asked Sarepta to halt shipments of Elevidys after three children who received the therapy died, including two from liver failure.&nbsp;The move ignited backlash from patient advocates and conservative media, who slammed the agency for standing in the way of what many families see as a last hope for kids battling a fatal condition.&nbsp;Replimune stated that the CRL for RP1 cited the Ignyte Phase 1/2 trial as lacking the rigor to support approval, due to heterogeneity in the patient population and concerns regarding the confirmatory study design. No safety issues were raised.&nbsp;The company plans to request a Type A meeting with the FDA to explore a path forward for accelerated approval.CEO Sushil Patel expressed surprise at the CRL, noting that the issues raised&nbsp;had not been&nbsp;discussed during the mid- and late-cycle reviews. RP1, engineered from a herpes simplex virus, is designed to directly kill tumors and trigger a systemic immune response.&nbsp;It’s the lead program in Replimune’s proprietary RPx platform, which the company believes can work&nbsp;independently or&nbsp;in conjunction with other cancer therapies.On Stocktwits, retail sentiment for Replimune was ‘extremely bullish’ late Wednesday amid a 1,038% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/REPL">Replimune’s stock</a> has declined nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around Replimune Group (REPL) surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral.’ (Photo credit: Getty Images)

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval

Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was based on trial design concerns.

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REPL News

REPLReplimune Group Inc